An 8-Week Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension.

Trial Profile

An 8-Week Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Aliskiren/amlodipine; Amlodipine
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms AACESS
  • Most Recent Events

    • 27 Apr 2012 Actual end date (August 2009) added as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Results published in the Journal of Clinical Hypertension (Greenwich).
    • 20 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top